President & CEO of Cytonics | Johns Hopkins School of Medicine | Moving From Insurmountable Challenge To Almost Certain Failure With Unbridled Enthusiasm
❗BREAKING❗1st Patient Dosed in Ph 1 Clinical Trial Last night 💉 we dosed our first patient in our Phase 1 clinical trial of CYT-108 for the treatment of osteoarthritis. The patient received 25mg of CYT-108, our recombinant Alpha-2-Macroglobulin variant. They were observed for 30 minutes and no acute adverse events were detected. This event marks our transition from a preclinical research company to a clinical-stage company, a massive milestone that underscores our commitment to transforming the treatment of osteoarthritis. 📅 Timeline and Next Steps This patient will receive their final dose in late September, with the last follow-up scheduled for January 2025. Over the next two months, we anticipate enrolling and dosing approximately 20 more patients, keeping us on track for the Phase 1 clinical report to be published in June 2025. Each step brings us closer to our goal of providing a disease-modifying treatment for osteoarthritis, potentially benefiting millions of patients worldwide. Many more updates to come! #arthritis #regenerativemedicine #clinicaltrials #Cytonics #biotechnology
Congrats Joey Bose, HUGE accomplishment. Wishing you and the entire Cytonics team the best!
A big congratulations, Joey and Team!
Congrats, Mr. Bose! Excited to be part of your investing pool!
Congratulations Joey Bose! Exciting times for Cytonics. Cheering you and your team on for a successful result and advancement to the next phase!
Amazing!
Congratulations Joey and team.